155 related articles for article (PubMed ID: 20507301)
1. Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy.
Dickinson M; Hoyt R; Roberts AW; Grigg A; Seymour JF; Prince HM; Szer J; Ritchie D
Br J Haematol; 2010 Jul; 150(1):39-45. PubMed ID: 20507301
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of [¹⁸F]fluoro-2-deoxy-D-glucose positron emission tomography for clinical outcome in patients with relapsed/refractory diffuse large B-cell lymphoma prior to and after autologous stem cell transplant.
Qiao W; Zhao J; Xing Y; Wang C; Wang T
Leuk Lymphoma; 2014 Feb; 55(2):276-82. PubMed ID: 23617323
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
Qiao W; Zhao J; Wang C; Wang T; Xing Y
Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
[TBL] [Abstract][Full Text] [Related]
4. Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients.
Roland V; Bodet-Milin C; Moreau A; Gastinne T; Mahé B; Dubruille V; Maisonneuve H; Juge-Morineau N; Moreau P; Jardel H; Planche L; Mohty M; Moreau P; Harousseau JL; Kraeber-Bodéré F; Le Gouill S
Bone Marrow Transplant; 2011 Mar; 46(3):393-9. PubMed ID: 20577223
[TBL] [Abstract][Full Text] [Related]
5. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma.
Derenzini E; Musuraca G; Fanti S; Stefoni V; Tani M; Alinari L; Venturini F; Gandolfi L; Baccarani M; Zinzani PL
Cancer; 2008 Nov; 113(9):2496-503. PubMed ID: 18833583
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation.
Smeltzer JP; Cashen AF; Zhang Q; Homb A; Dehdashti F; Abboud CN; Dipersio JF; Stockerl-Goldstein KE; Uy GL; Vij R; Westervelt P; Bartlett NL; Fehniger TA
Biol Blood Marrow Transplant; 2011 Nov; 17(11):1646-52. PubMed ID: 21601641
[TBL] [Abstract][Full Text] [Related]
7. Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT.
Akhtar S; Al-Sugair AS; Abouzied M; Alkadhi Y; Dingle M; Abdelsalam M; Soudy H; Darwish A; Eltigani A; Elhassan TA; Nabil-Ahmed M; Maghfoor I
Bone Marrow Transplant; 2013 Nov; 48(12):1530-6. PubMed ID: 23749108
[TBL] [Abstract][Full Text] [Related]
8. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.
Moskowitz CH; Schöder H; Teruya-Feldstein J; Sima C; Iasonos A; Portlock CS; Straus D; Noy A; Palomba ML; O'Connor OA; Horwitz S; Weaver SA; Meikle JL; Filippa DA; Caravelli JF; Hamlin PA; Zelenetz AD
J Clin Oncol; 2010 Apr; 28(11):1896-903. PubMed ID: 20212248
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era.
Armand P; Welch S; Kim HT; LaCasce AS; Jacobsen ED; Davids MS; Jacobson C; Fisher DC; Brown JR; Coughlin E; Freedman AS; Chen YB
Br J Haematol; 2013 Mar; 160(5):608-17. PubMed ID: 23278720
[TBL] [Abstract][Full Text] [Related]
10. The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma.
Hoppe BS; Moskowitz CH; Zhang Z; Maragulia JC; Rice RD; Reiner AS; Hamlin PA; Zelenetz AD; Yahalom J
Bone Marrow Transplant; 2009 Jun; 43(12):941-8. PubMed ID: 19139730
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation.
Svoboda J; Andreadis C; Elstrom R; Chong EA; Downs LH; Berkowitz A; Luger SM; Porter DL; Nasta S; Tsai D; Loren AW; Siegel DL; Glatstein E; Alavi A; Stadtmauer EA; Schuster SJ
Bone Marrow Transplant; 2006 Aug; 38(3):211-6. PubMed ID: 16770314
[TBL] [Abstract][Full Text] [Related]
12. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab.
Safar V; Dupuis J; Itti E; Jardin F; Fruchart C; Bardet S; Véra P; Copie-Bergman C; Rahmouni A; Tilly H; Meignan M; Haioun C
J Clin Oncol; 2012 Jan; 30(2):184-90. PubMed ID: 22162590
[TBL] [Abstract][Full Text] [Related]
13. Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival.
Sucak GT; Özkurt ZN; Suyani E; Yaşar DG; Akdemir ÖÜ; Aki Z; Yeğin ZA; Yağci M; Kapucu ÖL
Ann Hematol; 2011 Nov; 90(11):1329-36. PubMed ID: 21437590
[TBL] [Abstract][Full Text] [Related]
14. Pre-transplant (18)F-fluorodeoxyglucose positron emission tomography-based survival model in patients with aggressive lymphoma undergoing high-dose chemotherapy and autologous SCT.
Akhtar S; Al-Sugair AS; Abouzied M; Alkadhi Y; Dingle M; Abdelsalam M; Soudy H; Darwish A; Eltigani A; Elhassan TA; Nabil-Ahmed M; Maghfoor I
Bone Marrow Transplant; 2013 Apr; 48(4):551-6. PubMed ID: 22964592
[TBL] [Abstract][Full Text] [Related]
15. Are dynamic or fixed FDG-PET measures of disease of greater prognostic value in patients with relapsed/refractory diffuse large B-cell lymphoma undergoing autologous haematopoietic stem cell transplantation?
Campbell BA; Brown R; Lambertini A; Hofman MS; Bressel M; Seymour JF; Wirth A; MacManus M; Dickinson M
Br J Haematol; 2023 May; 201(3):502-509. PubMed ID: 37015002
[TBL] [Abstract][Full Text] [Related]
16. Impact of salvage treatment modalities in patients with positive FDG-PET/CT after R-CHOP chemotherapy for aggressive B-cell non-Hodgkin lymphoma.
Chin V; Fulham M; Hertzberg M; Jackson M; Lindeman R; Brighton T; Kidson-Gerber G; Wegner EA; Cheung C; MacCallum S; Williams J; Thompson SR
J Med Imaging Radiat Oncol; 2018 Jun; 62(3):432-439. PubMed ID: 29577608
[TBL] [Abstract][Full Text] [Related]
17. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.
Redondo AM; Pomares H; Vidal MJ; Pascual MJ; Quereda B; Sancho JM; Polo M; López J; Conde E; Jarque I; Alonso N; Ramírez MJ; Fernández P; Sayas MJ; Requena MJ; Salar A; González JD; González-Barca E; Arranz R; Caballero D; Martín A
Br J Haematol; 2014 Mar; 164(5):668-74. PubMed ID: 24274082
[TBL] [Abstract][Full Text] [Related]
18. Interim18 F-FLUORO-2-deoxy-d-glucose positron emission tomography scan/computed tomography scan in diffuse large B cell lymphoma-as a prognostic tool.
Basit A; Siddiqui N; Muzaffar N; Awan UK; Bashir H; Khan SA; Hameed A
J Pak Med Assoc; 2016 Apr; 66(4):380-6. PubMed ID: 27122261
[TBL] [Abstract][Full Text] [Related]
19. The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation.
Filmont JE; Gisselbrecht C; Cuenca X; Deville L; Ertault M; Brice P; De Kerviler E; Briere J; Larghero J; Moretti JL; Mounier N
Cancer; 2007 Sep; 110(6):1361-9. PubMed ID: 17623832
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant.
Cherng HJ; Xu G; Feng L; Steiner R; Fayad L; Strati P; Nair R; Nastoupil LJ; Lee HJ; Neelapu SS; Flowers CR; Rodriguez M; Wang M; Hagemeister F; Pinnix CC; Ramdial J; Srour S; Nieto Y; Rezvani K; Champlin R; Kebriaei P; Westin J; Macapinlac HA; Shpall E; Ahmed S
Br J Haematol; 2023 Jan; 200(1):35-44. PubMed ID: 36068929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]